Gary Levy1, Minnie Malik2, Joy Britten2, Melissa Gilden2, James Segars1, William H Catherino3. 1. Program in Reproductive and Adult Endocrinology Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, Maryland. 2. Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, Maryland. 3. Program in Reproductive and Adult Endocrinology Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, Maryland. Electronic address: william.catherino@usuhs.edu.
Abstract
OBJECTIVE: To investigate the impact of liarozole on transforming growth factor-β3 (TGF-β3) expression, TGF-β3 controlled profibrotic cytokines, and extracellular matrix formation in a three-dimensional (3D) leiomyoma model system. DESIGN: Molecular and immunohistochemical analysis in a cell line evaluated in a three-dimensional culture. SETTING: Laboratory study. PATIENT(S): None. INTERVENTION(S): Treatment of leiomyoma and myometrial cells with liarozole and TGF-β3 in a three-dimensional culture system. MAIN OUTCOME MEASURE(S): Quantitative real-time reverse-transcriptase polymerase chain reaction and Western blotting to assess fold gene and protein expression of TGF-β3 and TGF-β3 regulated fibrotic cytokines: collagen 1A1 (COL1A1), fibronectin, and versican before and after treatment with liarozole, and confirmatory immunohistochemical stains of treated three-dimensional cultures. RESULT(S): Both TGF-β3 gene and protein expression were elevated in leiomyoma cells compared with myometrium in two-dimensional and 3D cultures. Treatment with liarozole decreased TGF-β3 gene and protein expression. Extracellular matrix components versican, COL1A1, and fibronectin were also decreased by liarozole treatment in 3D cultures. Treatment of 3D cultures with TGF-β3 increased gene expression and protein production of COL1A1, fibronectin, and versican. CONCLUSION(S): Liarozole decreased TGF-β3 and TGF-β3-mediated extracellular matrix expression in a 3D uterine leiomyoma culture system. Published by Elsevier Inc.
OBJECTIVE: To investigate the impact of liarozole on transforming growth factor-β3 (TGF-β3) expression, TGF-β3 controlled profibrotic cytokines, and extracellular matrix formation in a three-dimensional (3D) leiomyoma model system. DESIGN: Molecular and immunohistochemical analysis in a cell line evaluated in a three-dimensional culture. SETTING: Laboratory study. PATIENT(S): None. INTERVENTION(S): Treatment of leiomyoma and myometrial cells with liarozole and TGF-β3 in a three-dimensional culture system. MAIN OUTCOME MEASURE(S): Quantitative real-time reverse-transcriptase polymerase chain reaction and Western blotting to assess fold gene and protein expression of TGF-β3 and TGF-β3 regulated fibrotic cytokines: collagen 1A1 (COL1A1), fibronectin, and versican before and after treatment with liarozole, and confirmatory immunohistochemical stains of treated three-dimensional cultures. RESULT(S): Both TGF-β3 gene and protein expression were elevated in leiomyoma cells compared with myometrium in two-dimensional and 3D cultures. Treatment with liarozole decreased TGF-β3 gene and protein expression. Extracellular matrix components versican, COL1A1, and fibronectin were also decreased by liarozole treatment in 3D cultures. Treatment of 3D cultures with TGF-β3 increased gene expression and protein production of COL1A1, fibronectin, and versican. CONCLUSION(S): Liarozole decreased TGF-β3 and TGF-β3-mediated extracellular matrix expression in a 3D uterine leiomyoma culture system. Published by Elsevier Inc.
Authors: D I Axel; A Frigge; J Dittmann; H Runge; I Spyridopoulos; R Riessen; R Viebahn; K R Karsch Journal: Cardiovasc Res Date: 2001-03 Impact factor: 10.787
Authors: Evan R Myers; Matthew D Barber; Tara Gustilo-Ashby; Grace Couchman; David B Matchar; Douglas C McCrory Journal: Obstet Gynecol Date: 2002-07 Impact factor: 7.661
Authors: Donna Day Baird; David B Dunson; Michael C Hill; Deborah Cousins; Joel M Schectman Journal: Am J Obstet Gynecol Date: 2003-01 Impact factor: 8.661
Authors: Sinnie Sin Man Ng; Soledad Jorge; Minnie Malik; Joy Britten; Szu-Chi Su; Charles R Armstrong; Joshua T Brennan; Sydney Chang; Kimberlyn Maravet Baig; Paul H Driggers; James H Segars Journal: J Clin Endocrinol Metab Date: 2019-03-01 Impact factor: 5.958
Authors: Qiwei Yang; Michal Ciebiera; Maria Victoria Bariani; Mohamed Ali; Hoda Elkafas; Thomas G Boyer; Ayman Al-Hendy Journal: Endocr Rev Date: 2022-07-13 Impact factor: 25.261
Authors: Eden R Cardozo; Rosemary Foster; Anatte E Karmon; Amy E Lee; Leah W Gatune; Bo R Rueda; Aaron K Styer Journal: Reprod Biol Endocrinol Date: 2018-05-11 Impact factor: 5.211